menu
    • menu
    [{"orgOrder":0,"company":"SteinCares","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"SteinCares","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SteinCares \/ SteinCares","highestDevelopmentStatusID":"15","companyTruncated":"SteinCares \/ SteinCares"},{"orgOrder":0,"company":"SteinCares","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"COSTA RICA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SteinCares","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"SteinCares \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"SteinCares \/ Lupin Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by SteinCares

    Menu

    SteinCares

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SteinCares

                            Costa Rica arrow
                            Coatings Trends
                            Not Confirmed

                            SteinCares

                            Costa Rica arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lupin Inks Licensing Deal to Supply Biosimilar Ranibizumab in Latin America

                            Details : SteinCares will handle all regulatory filings, registrations and commercialisation of LUBT010 (ranibizumab) in Latin America, while Lupin will be responsible for manufacturing the same.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 26, 2025

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SteinCares

                            Costa Rica arrow
                            Coatings Trends
                            Not Confirmed

                            SteinCares

                            Costa Rica arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : CStone Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CStone Partners with SteinCares to Market Sugemalimab in Latin America

                            Details : Under this agreement, SteinCares will gain the commercialization rights for Cejemly (sugemalimab) in 10 LATAM countries.

                            Product Name : Cejemly

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 26, 2025

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : CStone Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth